Payment overview · 2025
General Payments
$267.72
13 reported records · 7 companies
Healthcare provider profile · identity verified
Marc A Matozzo, DO
Allopathic & Osteopathic Physicians|Family Medicine · PHILADELPHIA, PA · NPI 1437156098
Verified facts
What the public records show
CMS Open Payments records show Marc A Matozzo, DO received $267.72 in general payments during 2025 across 13 reported records.
Novo Nordisk Inc accounted for 41.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $110.29 | 41.2% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $49.66 | 18.6% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $31.05 | 11.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $24.91 | 9.3% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $22.04 | 8.2% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.92 | 6.0% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $13.85 | 5.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $267.72 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $90.14 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $55.96 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.66 | 2 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $22.04 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $17.00 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $13.85 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $13.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
128 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Alprazolam | Alprazolam | 552 | 72 |
| Atorvastatin Calcium | Atorvastatin Calcium | 328 | 100 |
| Azithromycin | Azithromycin | 324 | 210 |
| Oxycodone Hcl | Oxycodone Hcl | 290 | 30 |
| Omeprazole | Omeprazole | 283 | 94 |
| Metoprolol Succinate | Metoprolol Succinate | 263 | 85 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 224 | 81 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 217 | 83 |
| Losartan Potassium | Losartan Potassium | 215 | 74 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 209 | 26 |
| Lorazepam | Lorazepam | 197 | 38 |
| Diazepam | Diazepam | 193 | 30 |
| Levothyroxine Sodium | Levothyroxine Sodium | 180 | 55 |
| Escitalopram Oxalate | Escitalopram Oxalate | 179 | 56 |
| Amlodipine Besylate | Amlodipine Besylate | 177 | 62 |
| Prednisone | Prednisone | 154 | 84 |
| Metformin Hcl | Metformin Hcl | 149 | 50 |
| Furosemide | Furosemide | 145 | 48 |
| Ibuprofen | Ibuprofen | 139 | 46 |
| Amoxicillin | Amoxicillin | 131 | 89 |
| Gabapentin | Gabapentin | 130 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 129 | 18 |
| Ozempic | Semaglutide | 128 | 30 |
| Eliquis | Apixaban | 126 | 24 |
| Tramadol Hcl | Tramadol Hcl | 125 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 118 | 46 |
| Zolpidem Tartrate | Zolpidem Tartrate | 114 | 24 |
| Lisinopril | Lisinopril | 104 | 35 |
| Fluticasone Propionate | Fluticasone Propionate | 96 | 43 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 87 | 67 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 82 | 63 |
| Clonazepam | Clonazepam | 82 | 12 |
| Famotidine | Famotidine | 82 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 79 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 77 | 29 |
| Montelukast Sodium | Montelukast Sodium | 70 | 25 |
| Valacyclovir | Valacyclovir Hcl | 69 | 25 |
| Sertraline Hcl | Sertraline Hcl | 68 | 22 |
| Glipizide Er | Glipizide | 67 | 22 |
| Meloxicam | Meloxicam | 66 | 31 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 66 | 22 |
| Simvastatin | Simvastatin | 64 | 22 |
| Baclofen | Baclofen | 63 | 35 |
| Trazodone Hcl | Trazodone Hcl | 61 | 21 |
| Methylprednisolone | Methylprednisolone | 53 | 40 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 50 | 14 |
| Celecoxib | Celecoxib | 47 | 12 |
| Glimepiride | Glimepiride | 47 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 46 | 12 |
| Temazepam | Temazepam | 46 | suppressed |
| Allopurinol | Allopurinol | 44 | 15 |
| Cephalexin | Cephalexin | 44 | 29 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 44 | 26 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 41 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 12 |
| Levofloxacin | Levofloxacin | 40 | 30 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 39 | 15 |
| Meclizine Hcl | Meclizine Hcl | 39 | 22 |
| Mirtazapine | Mirtazapine | 39 | suppressed |
| Mounjaro | Tirzepatide | 39 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 38 | 16 |
| Ezetimibe | Ezetimibe | 37 | 13 |
| Hydrocortisone | Hydrocortisone | 37 | 24 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 36 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 36 | suppressed |
| Potassium Chloride | Potassium Chloride | 35 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 33 | 11 |
| Lovastatin | Lovastatin | 33 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Fluconazole | Fluconazole | 28 | 12 |
| Bupropion Hcl | Bupropion Hcl | 27 | suppressed |
| Carvedilol | Carvedilol | 27 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 26 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | 14 |
| Valsartan | Valsartan | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Naproxen | Naproxen | 23 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 22 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 22 | 17 |
| Rybelsus | Semaglutide | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 21 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 19 |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 16 |
| Incruse Ellipta | Umeclidinium Bromide | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Oxycontin | Oxycodone Hcl | 20 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Colchicine | Colchicine | 19 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Metronidazole | Metronidazole | 19 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 16 | 14 |
| Nystatin | Nystatin | 16 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Pregabalin | Pregabalin | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Tretinoin | Tretinoin | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 12 | suppressed |
| Roflumilast | Roflumilast | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 11 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $267.72 · 13 records | Novo Nordisk Inc | APTIMA, JARDIANCE, MOUNJARO, Natroba, REXULTI, Spinosad, Wegovy, ZORYVE | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error